$NRIX
Nurix Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000156459022003007 Filed on January 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $9.621M $7.396M $29.75M
YoY Change 92.0% 10.57% 66.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.228M $8.818M $31.20M
YoY Change 41.32% 41.09% 91.31%
% of Gross Profit
Research & Development $43.14M $36.53M $116.4M
YoY Change 87.53% 78.64% 75.1%
% of Gross Profit
Depreciation & Amortization $991.0K $757.0K $2.790M
YoY Change 54.84% 18.28% 27.98%
% of Gross Profit
Operating Expenses $52.37M $45.35M $147.6M
YoY Change 77.31% 69.85% 78.3%
Operating Profit -$42.74M -$117.9M
YoY Change 74.31% 81.41%
Interest Expense $211.0K $295.0K $823.0K
YoY Change -34.06% 110.71% -31.98%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$42.53M -$37.66M -$117.1M
YoY Change 75.73% 89.52% 83.55%
Income Tax $0.00 $44.00K $131.0K
% Of Pretax Income
Net Earnings -$42.53M -$37.70M -$117.2M
YoY Change 75.21% 89.32% 171.02%
Net Earnings / Revenue -442.09% -509.76% -393.93%
Basic Earnings Per Share -$0.95 -$2.73
Diluted Earnings Per Share -$951.7K -$846.3K -$2.732M
COMMON SHARES
Basic Shares Outstanding 44.74M 42.90M shares
Diluted Shares Outstanding 44.69M shares 42.90M shares

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $261.1M $295.4M $295.4M
YoY Change -13.86% 5.14% 5.14%
Cash & Equivalents $78.78M $80.51M $80.22M
Short-Term Investments $183.2M $215.2M $215.2M
Other Short-Term Assets $11.20M $9.480M $9.480M
YoY Change 202.78% 55.41% 55.41%
Inventory
Prepaid Expenses
Receivables $8.000M $6.000M $6.000M
Other Receivables $204.0K $204.0K $204.0K
Total Short-Term Assets $280.5M $311.1M $311.1M
YoY Change -9.74% 4.25% 4.26%
LONG-TERM ASSETS
Property, Plant & Equipment $13.52M $11.34M $25.35M
YoY Change 94.28% 69.96% 278.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $123.7M $137.2M $137.2M
YoY Change 60.21% 50.92% 50.92%
Other Assets $4.157M $2.833M $3.119M
YoY Change 164.61% 1500.56% 939.67%
Total Long-Term Assets $157.2M $165.7M $165.7M
YoY Change 83.06% 69.19% 69.21%
TOTAL ASSETS
Total Short-Term Assets $280.5M $311.1M $311.1M
Total Long-Term Assets $157.2M $165.7M $165.7M
Total Assets $437.7M $476.8M $476.8M
YoY Change 10.35% 20.29% 20.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.014M $6.650M $6.650M
YoY Change 37.06% 94.9% 95.59%
Accrued Expenses $16.85M $18.40M $18.40M
YoY Change 56.01% 121.64% 121.64%
Deferred Revenue $43.19M $41.21M
YoY Change 31.86% 25.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $66.05M $66.26M $66.26M
YoY Change 37.68% 48.76% 48.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $65.75M $68.21M $68.21M
YoY Change 7803.13% 7924.82% 10.91%
Total Long-Term Liabilities $65.75M $68.21M $68.21M
YoY Change 7803.13% 7924.82% 10.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $66.05M $66.26M $66.26M
Total Long-Term Liabilities $65.75M $68.21M $68.21M
Total Liabilities $131.8M $134.5M $134.5M
YoY Change 4.17% 26.77% 26.74%
SHAREHOLDERS EQUITY
Retained Earnings -$263.4M -$220.9M
YoY Change 105.82% 113.01%
Common Stock $563.8M
YoY Change 43.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $305.9M $342.3M $342.3M
YoY Change
Total Liabilities & Shareholders Equity $437.7M $476.8M $476.8M
YoY Change 10.35% 20.29% 20.31%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$42.53M -$37.70M -$117.2M
YoY Change 75.21% 89.32% 171.02%
Depreciation, Depletion And Amortization $991.0K $757.0K $2.790M
YoY Change 54.84% 18.28% 27.98%
Cash From Operating Activities -$42.60M -$30.91M -$84.40M
YoY Change -629.0% 50.93% 105400.0%
INVESTING ACTIVITIES
Capital Expenditures $3.472M -$862.0K $5.661M
YoY Change 311.86% -4.22% 24.34%
Acquisitions
YoY Change
Other Investing Activities $43.50M -$35.66M -$102.6M
YoY Change -2924.87% -71.16% -58.94%
Cash From Investing Activities $40.03M -$36.52M -$108.3M
YoY Change -1777.04% -70.68% -57.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.488M 500.0K 153.9M
YoY Change 9.49% -144.25% -54.61%
NET CHANGE
Cash From Operating Activities -42.60M -30.91M -84.40M
Cash From Investing Activities 40.03M -36.52M -108.3M
Cash From Financing Activities 1.488M 500.0K 153.9M
Net Change In Cash -1.111M -66.93M -38.73M
YoY Change -115.81% -54.21% -145.82%
FREE CASH FLOW
Cash From Operating Activities -$42.60M -$30.91M -$84.40M
Capital Expenditures $3.472M -$862.0K $5.661M
Free Cash Flow -$46.07M -$30.05M -$90.06M
YoY Change -739.0% 53.47% 1843.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity File Number
EntityFileNumber
001-39398
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2021 dei City Area Code
CityAreaCode
415
CY2021 dei Local Phone Number
LocalPhoneNumber
660-5320
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2021 nrix Net Operating Loss Carryback Period Cares Act
NetOperatingLossCarrybackPeriodCARESAct
P5Y
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
NRIX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1100000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44737768
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80506000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
215214000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6000000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66258000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
59022000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44664371
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44664371
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
45000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563757000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-608000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220892000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
476771000
CY2021 us-gaap Revenues
Revenues
29750000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66494000
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
3846000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
298434000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
90890000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14005000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6672000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
286000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
170000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2833000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
177000
CY2021Q4 us-gaap Assets
Assets
476771000
CY2020Q4 us-gaap Assets
Assets
396343000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6650000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3412000
CY2021Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
14549000
CY2020Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
8328000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3847000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
41212000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32799000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44539000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60685000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
850000
CY2021Q4 us-gaap Liabilities
Liabilities
134469000
CY2020Q4 us-gaap Liabilities
Liabilities
106074000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
39000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
393841000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103698000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
290269000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396343000
CY2020 us-gaap Revenues
Revenues
17820000
CY2019 us-gaap Revenues
Revenues
31115000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8326000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117063000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.76
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.59
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42895383
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15673424
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3292514
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
28400000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-43242000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
89000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117889000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43153000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21697000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-36847000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2019 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
216000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21699000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-57714000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
168109000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
218147000
CY2020 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
129000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4301000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
89000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-43242000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
290269000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150157000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1666000
CY2021 us-gaap Profit Loss
ProfitLoss
-117194000
CY2020 us-gaap Profit Loss
ProfitLoss
-43242000
CY2019 us-gaap Profit Loss
ProfitLoss
-21699000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2790000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2180000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2354000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
15800000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4301000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
510000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1706000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-273000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
109000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-128000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3292000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-7500000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
7500000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000000
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3642000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3846000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5442000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3941000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1589000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1234000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
302000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6750000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
48179000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16885000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5144000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
6218000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2282000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2373000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84365000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
601000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
348497000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
275224000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
9351000
CY2021 nrix Proceeds From Sales Of Investments
ProceedsFromSalesOfInvestments
6994000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
238913000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25373000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5661000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8498000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
218147000
CY2020 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
119914000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1666000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
970000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
142000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2060000
CY2021 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000
CY2020 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
7000
CY2019 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
16000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153882000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339024000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38734000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34986000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
481000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2371000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2505000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
580000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
152000
CY2021 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
239000
CY2020 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
129000
CY2019 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
216000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
168109000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80506000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
286000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
170000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
170000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34986000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117200000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84400000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220900000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
295700000
CY2021Q4 nrix Working Capital
WorkingCapital
244900000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-3
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and investments. The Company’s investments consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or investments. </p>
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
500000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2019 nrix Proceeds From Milestone Payments
ProceedsFromMilestonePayments
0
CY2019 nrix Milestone Revenues Recognized
MilestoneRevenuesRecognized
0
CY2019 nrix Substantive Milestones
SubstantiveMilestones
0
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13183000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2800000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19855000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14879000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6672000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26219000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2400000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8854000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5725000
CY2021Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
4158000
CY2020Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
1238000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
75000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
74000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
659000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
700000
CY2021Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
14549000
CY2020Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
8328000
CY2021Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2020Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2020 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2019 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2015Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2021 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In November 2017, the Company entered into an amendment to its original lease agreement that combined the Company’s two leases into a single lease agreement and extended the term of the lease agreement through April 30, 2025
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-04-30
CY2021 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
The Company has an option to renew this lease for an additional two years which has not been included in the lease term used to calculate the ROU asset and lease liability as it is not reasonably certain that the Company will exercise this option.
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
91000
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P14M
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2021Q3 nrix Operating Lease Rent Payable Per Month
OperatingLeaseRentPayablePerMonth
100000
CY2021Q3 nrix Percentage Of Increase Of Annual Rent
PercentageOfIncreaseOfAnnualRent
0.03
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3800000
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
100000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14000000.0
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3800000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9200000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
4000000.0
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0313
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9476306
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-203000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
3023000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
2927000
CY2019 us-gaap Sublease Income
SubleaseIncome
311000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3023000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2616000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5197000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5563000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5060000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1738000
CY2021Q4 nrix Lessee Operating Lease Liability Payments Due Including Mission Bay Lease And Imputed Interest
LesseeOperatingLeaseLiabilityPaymentsDueIncludingMissionBayLeaseAndImputedInterest
17558000
CY2021Q4 nrix Lessee Operating Lease Liability Undiscounted Lease Payments Related To Mission Bay Lease
LesseeOperatingLeaseLiabilityUndiscountedLeasePaymentsRelatedToMissionBayLease
3785000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
737000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13036000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8153546
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15900000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3400000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2021Q4 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
58794
CY2021Q4 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
300000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.15
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.50
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.41
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12000000.0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3100000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
57900000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y18D
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
100000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-20500000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
200000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-117063000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-63777000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21460000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117063000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63777000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21460000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-20577000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
238000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
334000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
42000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20535000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
239000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.102
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.045
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.040
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.066
CY2020 nrix Effective Income Tax Rate Reconciliation Unrecognized Income Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedIncomeTaxBenefits
0.006
CY2019 nrix Effective Income Tax Rate Reconciliation Unrecognized Income Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedIncomeTaxBenefits
-0.010
CY2020 nrix Effective Income Tax Rate Reconciliation Federal Rate Impact Due To Cares Act
EffectiveIncomeTaxRateReconciliationFederalRateImpactDueToCARESAct
0.131
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.012
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.293
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.103
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.370
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.024
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.322
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41081000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25145000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
17502000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9330000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
21874000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
10536000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1054000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
773000
CY2021Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
1896000
CY2020Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
1624000
CY2021Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
3436000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
86843000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47408000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
83517000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47408000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3326000
CY2021Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3326000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3326000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
36100000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7600000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8500000
CY2021Q4 nrix Net Operating Loss Unutilized Amount
NetOperatingLossUnutilizedAmount
400000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6300000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4589886
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14867072
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5361000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2920000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2157000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2295000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
137000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2282000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1326000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
626000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1313000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1180000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6331000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5361000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2920000
CY2021 nrix Income Tax Decrease In Tax Credits Research Amount
IncomeTaxDecreaseInTaxCreditsResearchAmount
1300000
CY2020 nrix Net Operating Loss Carryback Refund Claim Cares Act
NetOperatingLossCarrybackRefundClaimCARESAct
19600000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-43242000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21699000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42895383
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15673424
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3292514
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.76
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.59
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6008228

Files In Submission

Name View Source Status
0001564590-22-003007-index-headers.html Edgar Link pending
0001564590-22-003007-index.html Edgar Link pending
0001564590-22-003007.txt Edgar Link pending
0001564590-22-003007-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwmi2ibzk11t000001.jpg Edgar Link pending
gwmi2ibzk11t000002.jpg Edgar Link pending
gwmi2ibzk11t000003.jpg Edgar Link pending
gwmi2ibzk11t000004.jpg Edgar Link pending
gwmi2ibzk11t000005.jpg Edgar Link pending
gwmi2ibzk11t000006.jpg Edgar Link pending
gwmi2ibzk11t000007.jpg Edgar Link pending
gwmi2ibzk11t000008.jpg Edgar Link pending
gwmi2ibzk11t000009.jpg Edgar Link pending
gwmi2ibzk11t000010.jpg Edgar Link pending
gwmi2ibzk11t000011.jpg Edgar Link pending
gwmi2ibzk11t000012.jpg Edgar Link pending
gwmi2ibzk11t000013.jpg Edgar Link pending
gwmi2ibzk11t000014.jpg Edgar Link pending
gwmi2ibzk11t000015.jpg Edgar Link pending
gwmi2ibzk11t000016.jpg Edgar Link pending
gwmi2ibzk11t000017.jpg Edgar Link pending
gwmi2ibzk11t000018.jpg Edgar Link pending
gwmi2ibzk11t000019.jpg Edgar Link pending
gwmi2ibzk11t000020.jpg Edgar Link pending
gwmi2ibzk11t000021.jpg Edgar Link pending
gwmi2ibzk11t000022.jpg Edgar Link pending
gwmi2ibzk11t000023.jpg Edgar Link pending
gwmi2ibzk11t000024.jpg Edgar Link pending
gwmi2ibzk11t000025.jpg Edgar Link pending
gwmi2ibzk11t000026.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-10k_20211130.htm Edgar Link pending
nrix-10k_20211130_htm.xml Edgar Link completed
nrix-20211130.xsd Edgar Link pending
nrix-20211130_cal.xml Edgar Link unprocessable
nrix-20211130_def.xml Edgar Link unprocessable
nrix-20211130_lab.xml Edgar Link unprocessable
nrix-20211130_pre.xml Edgar Link unprocessable
nrix-ex1011_579.htm Edgar Link pending
nrix-ex109_580.htm Edgar Link pending
nrix-ex211_11.htm Edgar Link pending
nrix-ex231_13.htm Edgar Link pending
nrix-ex311_7.htm Edgar Link pending
nrix-ex312_6.htm Edgar Link pending
nrix-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending